Currently Viewing:
Newsroom
Currently Reading
Study Probes How Severe Asthma Might Develop Through Allergic Inflammation
August 17, 2018 – David Bai
Healthcare Costs Reduced When Osteoporosis Drugs Used Consistently, Study Says
August 17, 2018 – Allison Inserro
Vitamin D3 Status and MS Susceptibility is Genotype Dependent, Study Finds
August 17, 2018 – Alison Rodriguez
Experts Assess Link Between Misclassification of Obesity and Prevalence of Migraine
August 17, 2018 – Alison Rodriguez
What We're Reading: Free Medical School Tuition; NJ Reinsurance Program; Downplaying Addiction With Opioids
August 17, 2018 – AJMC Staff
AJMC® in the Press, August 17, 2018
August 17, 2018 – AJMC Staff
This Week in Managed Care: August 17, 2018
August 17, 2018
FDA Gives Teva Green Light for First Generic EpiPen
August 16, 2018 – Allison Inserro
PARP Inhibitor Increases PFS Over Chemotherapy in Advanced Breast Cancers, Study Finds
August 16, 2018 – Samantha DiGrande

Ribociclib Approved as Front-Line Therapy for HR+/HER2- Breast Cancer

Laura Joszt
The FDA has approved Novartisí ribociclib (Kisqali) for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!